Puma Biotechnology is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer
The company primarily concentrates on discovering and advancing targeted cancer therapies, with a specific emphasis on developing novel drugs that can improve the outcomes for patients with various forms of cancer. Their research is centered on precision medicine, aiming to tailor treatments based on the individual characteristics of each patient's tumor, thereby enhancing efficacy and reducing side effects. Through its commitment to scientific advancement and collaboration, Puma Biotechnology seeks to address unmet medical needs in oncology and contribute to the evolution of cancer treatment.
A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment.
Gainers SCYNEXIS, Inc. (NASDAQSCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront payment of $90 million.
Gainers ObsEva SA (NASDAQOBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.
Gainers Imago BioSciences, Inc. (NASDAQIMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash.
